Apellis’s anti-C3 Syfovre (pegcetacoplan intravitreal injection) and Astellas’ anti-C5 Izervay (avacincaptad pegol intravitreal injection) were both recently FDA-approved to treat Geographic Atrophy (GA), but physicians are eager for more treatment options, according to findings from…